1 – 29 of 29
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
(
- Contribution to journal › Article
-
Mark
Annual direct medical cost of active systemic lupus erythematosus in five European countries
(
- Contribution to journal › Article
- 2013
-
Mark
Health economic evaluation: why? When? How?
(
- Contribution to journal › Scientific review
-
Mark
The Comparison of Trial Data-Based and Registry Data-Based Cost-Effectiveness of Infliximab Treatment for Rheumatoid Arthritis in Sweden Using a Modeling Approach
(
- Contribution to journal › Article
-
Mark
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice
(
- Contribution to journal › Article
- 2012
-
Mark
Economic studies in rheumatology: data, perspectives, challenges.
(
- Contribution to journal › Article
-
Mark
Cost of multiple sclerosis in the Czech Republic: The COMS study
(
- Contribution to journal › Article
-
Mark
A framework for improving the quality of care for people with psoriasis
(
- Contribution to journal › Article
- 2011
-
Mark
Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment.
(
- Contribution to journal › Article
-
Mark
Cost of disorders of the brain in Europe 2010
(
- Contribution to journal › Article
- 2010
-
Mark
Cost of Illness from the Public Payers' Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care.
(
- Contribution to journal › Article
- 2009
-
Mark
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden
(
- Contribution to journal › Article
-
Mark
Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data
(
- Contribution to journal › Article
-
Mark
The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
(
- Contribution to journal › Article
- 2008
-
Mark
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
(
- Contribution to journal › Article
-
Mark
The burden of rheumatoid arthritis and access to treatment: health burden and costs
(
- Contribution to journal › Article
-
Mark
Patient access to rheumatoid arthritis treatments
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
(
- Contribution to journal › Article
-
Mark
The costs of treating glaucoma with combinations of topical drugs in Spain
(
- Contribution to journal › Article
-
Mark
The burden of rheumatoid arthritis and access to treatment: determinants of access
(
- Contribution to journal › Article
-
Mark
Disease status, costs and quality of life of patients with rheumatoid arthritis in France: The ECO-PR Study.
(
- Contribution to journal › Article
-
Mark
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
(
- Contribution to journal › Article
-
Mark
The burden of ankylosing spondylitis in Spain.
(
- Contribution to journal › Article
-
Mark
The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data.
(
- Contribution to journal › Article
- 2007
-
Mark
Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials
(
- Contribution to journal › Article
-
Mark
Costs of rheumatoid arthritis in Hungary
(
- Contribution to journal › Letter
- 2006
-
Mark
Health economic issues in rheumatoid arthritis
(
- Contribution to journal › Scientific review
-
Mark
Costs and quality of life of patients with multiple sclerosis in Europe
(
- Contribution to journal › Article
- 1998
-
Mark
Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany
(
- Contribution to journal › Article